Home > Journals > Minerva Cardiology and Angiology > Past Issues > Minerva Cardioangiologica 2018 December;66(6) > Minerva Cardioangiologica 2018 December;66(6):729-34

CURRENT ISSUE
 

JOURNAL TOOLS

Publishing options
eTOC
To subscribe PROMO
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Publication history
Reprints
Permissions
Cite this article as
Share

 

REVIEW  TRICUSPID VALVE INTERVENTIONS 

Minerva Cardioangiologica 2018 December;66(6):729-34

DOI: 10.23736/S0026-4725.18.04659-5

Copyright © 2018 EDIZIONI MINERVA MEDICA

language: English

Percutaneous tricuspid valve replacement: orthotopic and heterotopic valves

Kimberly ATIANZAR 1, Ming ZHANG 1, Sameer GAFOOR 1, 2

1 Swedish Heart and Vascular Institute, Seattle, WA, USA; 2 Cardiovascular Center Frankfurt, Frankfurt, Germany



The tricuspid valve has long been described as the “forgotten valve”, leaving tricuspid valve disease relatively neglected. However, the number of people in the United States affected by severe tricuspid regurgitation is growing. Isolated surgery for severe tricuspid regurgitation in the setting of right ventricular heart failure carries a high mortality risk, and therefore, attention to corrective therapies has increased. Because of the different etiologies for tricuspid regurgitation, multiple percutaneous transcatheter options for tricuspid valve repair for severe regurgitation are being studied and have been developed, including annuloplasty systems, leaflet and coaptation devices, vena caval (heterotopic) valve implantations, and tricuspid valve (orthotopic) replacement. In this paper, we review the heterotopic and orthotopic tricuspid valve transcatheter options for severe tricuspid regurgitation.


KEY WORDS: Tricuspid valve insufficiency - Transplantation, heterotopic - Surgery

top of page